See more : Japan Cash Machine Co., Ltd. (6418.T) Income Statement Analysis – Financial Results
Complete financial analysis of Gamida Cell Ltd. (GMDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gamida Cell Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Silver Viper Minerals Corp. (VIPRF) Income Statement Analysis – Financial Results
- Zignago Vetro S.p.A. (ZV.MI) Income Statement Analysis – Financial Results
- Nextware Ltd. (4814.T) Income Statement Analysis – Financial Results
- Hanwha Corporation (000885.KS) Income Statement Analysis – Financial Results
- McPhy Energy S.A. (0QTF.L) Income Statement Analysis – Financial Results
Gamida Cell Ltd. (GMDA)
About Gamida Cell Ltd.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.48M | 440.00K | 431.00K | 357.00K | 2.14M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.69M | -440.00K | -431.00K | -357.00K | -2.14M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -94.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 22.28M | 42.69M | 50.18M | 41.39M | 31.46M | 22.05M | 15.02M | 19.10M |
| General & Administrative | 44.58M | 19.40M | 16.98M | 12.17M | 12.09M | 11.60M | 4.47M | 4.61M |
| Selling & Marketing | 4.08M | 12.90K | 20.01K | 8.89K | 4.69K | 0.00 | 0.00 | 0.00 |
| SG&A | 48.67M | 19.40M | 16.98M | 12.17M | 12.09M | 11.60M | 4.47M | 4.61M |
| Other Expenses | -395.00K | 12.90M | 20.01M | 8.75M | 4.69M | 195.00K | -2.27M | 1.81M |
| Operating Expenses | 70.95M | 74.99M | 87.17M | 62.30M | 48.25M | 33.64M | 19.49M | 23.71M |
| Cost & Expenses | 74.43M | 74.99M | 87.17M | 62.30M | 48.25M | 33.64M | 19.49M | 23.71M |
| Interest Income | 2.73M | 4.38K | 2.63K | 236.00K | 17.15M | 1.04M | 330.00K | 163.00K |
| Interest Expense | 7.59M | 4.38M | 2.63M | 10.64M | 3.33M | 20.26M | 30.00K | 23.00K |
| Depreciation & Amortization | 2.02M | -149.55M | 431.00K | 2.63M | 19.29M | 269.00K | 162.00K | 124.00K |
| EBITDA | -70.62M | -74.55M | -86.74M | -60.57M | -28.95M | -32.60M | -20.16M | -24.48M |
| EBITDA Ratio | -3,958.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.64M | 74.99M | -87.17M | -62.30M | -48.25M | -33.64M | -19.49M | -23.71M |
| Operating Income Ratio | -4,071.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.65M | -4.38M | -2.63M | -648.00K | 13.82M | -19.22M | 479.00K | 1.04M |
| Income Before Tax | -63.00M | -79.38M | -89.79M | -72.70M | -34.42M | -52.86M | -19.01M | -22.67M |
| Income Before Tax Ratio | -3,531.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.00 | 74.99M | 2.63M | 3.74M | -70.00K | 70.00K | -479.00K | -1.04M |
| Net Income | -63.00M | -154.37M | -92.42M | -76.45M | -34.35M | -52.93M | -19.01M | -22.67M |
| Net Income Ratio | -3,531.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.57 | -2.42 | -1.56 | -1.75 | -1.17 | -10.53 | -1.06 | -1.26 |
| EPS Diluted | -0.57 | -2.42 | -1.56 | -1.75 | -1.16 | -10.53 | -1.06 | -1.26 |
| Weighted Avg Shares Out | 110.05M | 63.83M | 59.25M | 43.73M | 29.46M | 5.03M | 17.97M | 17.97M |
| Weighted Avg Shares Out (Dil) | 110.05M | 63.83M | 59.25M | 43.73M | 29.66M | 5.03M | 17.97M | 17.97M |
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved Gamida Cell’s allogeneic cell therapy, Omisirge® (omidubicel-onlv), for use in adult...
3 Hot Penny Stocks To Watch In The Stock Market Today
Penny stocks to watch this week. The post 3 Hot Penny Stocks To Watch In The Stock Market Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022. Net loss for 2022 was $79.4 million,...
Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022. Net loss for 2022 was $79.4 million,...
Gamida Cell Announces Changes to Board of Directors
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the resignation of Chairman Robert I. Blum. The Board of Directors has elected Shawn Cline Tomasello Chairwoman, effective immediately. “On behalf...
Gamida Cell Announces Changes to Board of Directors
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the resignation of Chairman Robert I. Blum. The Board of Directors has elected Shawn Cline Tomasello Chairwoman, effective immediately. “On behalf...
Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, March 27, 2023, at 8:00 a.m. ET...
Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the upcoming Oppenheimer 33rd Annual Healthcare Conference...
Data Presented on Gamida Cell's Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.
Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that two oral presentations and a poster presentation highlighting Gamida Cell’s investigational product candidates, omidubicel and GDA-201, were shared at the...
Source: https://incomestatements.info
Category: Stock Reports